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Introduction: Pulmonary hypertension (PH) is one of the most important
accompanying comorbidities with hemodialysis in patients with end-stage
renal disease. The prevalence of hemodialysisinduced PH is still a subject of
debate. The goal of the present work was to determine the prevalence of PH
in patients undergoing hemodialysis.
Materials and Methods: This study was carried out on 111 patients under-
going hemodialysis for at least 6 months. Pulmonary artery pressure (PAP)
was measured using echocardiography, and a value equal to or higher than
35mm Hg was considered PH. The relationship of a high PAP with demo-
graphic and clinical characteristics of the patients was assessed.
Results: A total of 111 patients were included in the study. The mean of
age was 44 ± 14 years. The mean duration of hemodialysis was 146 ± 80
months. The most common cause of endstage renal disease was Glomerulone-
phritis. The mean ejection fraction and PAP were 62,5 ± 10,5% (range, 29%
to 81%) and 26,6 ± 12 mmHg (range, 11 mmHg to 100 mmHg), respectively.
Overall, 16% of the patients had PH. These patients were more likely to have
low ejection fractions, valvular calcifications and valvulopathy. They were
also older than other patients.
Conclusion: Our findings show that PH is associated with duration age,
ejection fraction, and valvular calcifications. Due to the high prevalence of PH
among hemodialysis patients, it is necessary to screen this disorder and mini-
mize its effects.
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Background: Left heart diseases are the most common cause of pulmonary
hypertension (PH). The reactive form of PH confers a worse prognosis than
the passive one. Therapeutic intervention are going on investigating vasodila-
tion drugs.
Aims: The aim of this study was to seek for echocardiographic differences
between passive and reactive postcapillary pulmonary hypertension in patients
with heart failure and preserved ejection fraction.
Methods: This study enrolled 58 patients who were assigned both to pul-
monary artery catheterization and standard echocardiographic examination.
Patients were classified into 2 groups: reactive PH (mean pulmonary artery
pressure >25mmHg, pulmonary capillary wedge pressure >15 mmHg, and
transpulmonary gradient >12 mmHg) and passive PH (mean pulmonary artery
pressure >25mmHg, pulmonary capillary wedge pressure >15 mmHg, and
transpulmonary gradient < 12 mmHg).
Results: Despite similar wedge pressure (p = 0.67), patients with reactive
PH showed significantly higher systolic pulmonary artery pressure (p < 0.05)
and pulmonary arterial resistance (p < 0.05). There was a trend of correlation
with a better contractility measured by the lateral tricuspid annulus motion in
tissue Doppler imaging (10,2±2,1 vs. 8,3±1,9m/s, p = 0,094) and lower values
on the right ventricle long axis (73,8±12,4 vs. 80,1±23,5mm p = 0,05) in
patients with reactive PH compared with passive PH.
Conclusion: Despite higher pressure and resistance, patients with reactive
PH showed better right ventricular function and less remodeling.
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Background: Endothelial cell (EC) dysfunction plays a central role in the
pathogenesis of pulmonary arterial hypertension (PAH), promoting vasocon-
striction, smooth muscle proliferation and inflammation.
Objectives: This study sought to test the hypothesis that nebivolol, a β1
antagonist and β2,3-agonist, may improve PAH and reverse the PAH-related
phenotype of pulmonary ECs (P-EC).
Methods: We compared the effects of nebivolol, with metoprolol, a first
generation β1-selective β-blocker on human cultured PAH and control P-EC
proliferation, vasoactive and proinflammatory factor production and crosstalk
with PA smooth cells (PASMC). We assessed the effects of both β-blockers
in precontracted PA rings. We also compared the effects of both β-blockers in
experimentalPAH.
Results: PAH P-EC overexpressed the proinflammatory mediators IL-6
and MCP-1, the growth factor FGF2, and the potent vasoconstrictive agent
endothelin-1 as compared to control cells. This pathological phenotype was
corrected by nebivolol but not metoprolol in a dose-dependent fashion. We
confirmed that PAH P-EC proliferate more than control cells, and stimulate
more PASMC mitosis, a growth abnormality which was normalized by
nebivolol but not by metoprolol. Nebivolol but not metoprolol induced an
endothelium- and nitric oxide-dependant relaxation of PA. Nebivolol was
more potent than metoprolol in improving, cardiac function, pulmonary vas-
cular remodeling and inflammation of rats with monocrotaline-induced pulmo-
nary hypertension.
Conclusions: Nebivolol could be a promising option for the management
of PAH, improving endothelial dysfunction, pulmonary vascular remodeling,
and right heart function. Until clinical studies are undertaken, however, rou-
tine use of beta-blockers in PAH cannot be recommended.
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